Bristol, England — The rise of a potent synthetic opioid is raising alarms among health experts, with warnings that the UK may be on the brink of a public health crisis. The opioid, known as nitazenes, is linked to a surge in fatalities across the region, with local health officials reporting 22 deaths related to these substances in just 11 months.
Data from the Office for Health Improvement and Disparities covering June 2023 to May 2024 reveals the shocking impact of these compounds, particularly following a recent inquest in Wales. There, Gareth Jamie Thomas, 49, tragically succumbed to a heroin overdose combined with protonitazene. His death sheds light on a growing issue that many experts believe requires immediate attention.
Dave Tebbet from the Transform Drug Policy Foundation underscored the seriousness of the threat. “Nitazenes are infiltrating drug supplies across the UK, and we need to brace ourselves for the potential fallout,” he said. He emphasized that the situation is worsening and must be handled with urgency. While Bristol City Council reports no recent deaths from nitazenes in the city, public health officials assert that they are prepared to address emerging challenges posed by synthetic opioids.
Tebbet pointed out that over 70 variants of nitazenes exist, and while these drugs have been known since the 1950s, they have never received approval for medical use. Instead, they are predominantly found as adulterants mixed with heroin and prescription opioids like OxyContin. He noted that nitazenes are highly concentrated and can be 100 to 500 times more potent than heroin, making even minuscule amounts potentially lethal.
Further exacerbating the problem, nitazenes are becoming more prevalent in street drugs as the purity of heroin continues to decline. Data indicates that these synthetic opioids have been linked to 458 deaths across the UK in the last two years, a significant jump from the previous year. In contrast, fentanyl, another potent opioid, accounted for only 41 deaths in 2023, further illustrating the severe climb in nitazene-related fatalities.
To combat this burgeoning crisis, experts advocate for evidence-based harm reduction strategies, including drug testing services and supervised consumption sites. These measures aim to minimize the risks associated with opioid use and prevent accidental overdoses.
Bristol City Council has responded proactively, implementing a multi-agency initiative that includes enhanced access to treatment and education on reducing drug-related harm. Stephen Williams, chair of the Communities and Public Health Committee, expressed confidence in their current strategies. “We are committed to improving access to treatment and ensuring the community is informed about the risks associated with synthetic opioids,” he said.
In light of these challenges, the Transform Drug Policy Foundation is set to host an event on July 17 in City Hall aimed at discussing harm reduction strategies and the potential for Bristol to establish England’s first overdose prevention center. The community’s engagement and support could play a critical role in addressing the rise of nitazenes and safeguarding public health as the opioid crisis evolves.